Related references
Note: Only part of the references are listed.Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development
Apexa Bernard et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines
Hua Cheng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer
Thomas E. Stinchcombe et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems
Jun Yang et al.
AAPS JOURNAL (2010)
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21
Deok-Soo Son et al.
CANCER BIOLOGY & THERAPY (2010)
Modeling of tumor growth and anticancer effects of combination therapy
Gilbert Koch et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2009)
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells
Cecilia Ceresa et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100
N. F. Smith et al.
BRITISH JOURNAL OF CANCER (2008)
Annual Report to the Nation on the Status of Cancer, 1975-2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control
Ahmedin Jemal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells
Elisa Giovannetti et al.
MOLECULAR PHARMACOLOGY (2008)
Predicting the active doses in humans from animal studies: A novel approach in oncology
M. Rocchetti et al.
EUROPEAN JOURNAL OF CANCER (2007)
Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in
Zhiming Mai et al.
CARCINOGENESIS (2007)
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells
Tianhong Li et al.
CLINICAL CANCER RESEARCH (2007)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai et al.
NATURE PROTOCOLS (2006)
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
FDA drug approval summary:: Erlotinib (Tarceva®) tablets
MH Cohen et al.
ONCOLOGIST (2005)
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors
M. P. Morelli et al.
ANNALS OF ONCOLOGY (2005)
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents
M Simeoni et al.
CANCER RESEARCH (2004)
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs
ML Immordino et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models
B Higgins et al.
ANTI-CANCER DRUGS (2004)
Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma
F Meyer et al.
CHEMOTHERAPY (2004)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
